Patent SG-11201901961S-A (SG)
Title: Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
Inventor: YONEYAMA KOICHIRO
IPC: A61P7/04
Filed: 2017-09-05
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111H11111110111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/047813 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 39/395 (2006.01) A61P 7/04 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/JP2017/031933 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 05 September 2017 (05.09.2017) patent (Rule 4.17(ii)) (25) Filing Language: English Published: (26) Publication Language: English — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/383,933 06 September 2016 (06.09.2016) US 62/437,281 21 December 2016 (21.12.2016) US 62/485,514 14 April 2017 (14.04.2017) US (71) Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543 (JP). F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, Basel, CH4070 (CH). (72) Inventors: YONEYAMA, Koichiro; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-1, Nihon- bashi-Muromachi 2-chome, Chuo-ku, Tokyo, 1038324 (JP). SCHMITT, Christophe; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, CH4070 (CH). = (74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RS, RU, RW, SA, QA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated (84) States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, protection GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 en (54) Title: METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR - ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FAC- GC TOR X IN C (57) : An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for ---- preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that GC by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation 1-1 © factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X N according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented 0 and/or treated more effectively.